Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercialization of GRAFAPEX™ (treosulfan) for Injection in the United States and on certain recent capital allocation and capital structure developments and announced company management's participation in two upcoming investor conferences. All dollar amounts in this news release are in US dollars unle
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-15 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Patient Safety Must Remain the Foundation of Scope of Practice Decisions in Canada
Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - As scope of practice expansion is actively being considered across Canada, the Canadian Ophthalmological Society (COS) is emphasizing that patient safety must remain the central and non-negotiable principle guiding any changes to healthcare delivery. While COS supports innovation and system modernization, it is deeply concerned that several proposed changes would expand independent clinical authority to non-physician providers without
Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-15 12:05 PM EDT | Canadian Ophthalmological Society (COS)
La sécurité des patients doit demeurer le fondement des décisions relatives au champ de pratique au Canada
Ottawa, Ontario--(Newsfile Corp. - 15 avril 2026) - Alors que l'élargissement des champs de pratique est activement envisagé à travers le Canada, la Société canadienne d'ophtalmologie (SCO) rappelle que la sécurité des patients doit demeurer le principe central et non négociable guidant toute évolution de la prestation des soins de santé. Bien que la SCO appuie l'innovation et la modernisation du système, elle demeure profondém
Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-15 12:05 PM EDT | Canadian Ophthalmological Society (COS)
Scryb Approves Proposed Name Change and Grant of Stock Options
Toronto, Ontario--(Newsfile Corp. - April 15, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company"), is pleased to announce that it intends to complete its corporate name change to NorthPalm Capital Corp., marking the next phase in the Company's evolution and reflecting a renewed strategic focus on shareholder value creation and disciplined growth. Under the new NorthPalm Capital, the Company plans to focus on timing, execution, and high-growth opportunities, suppo
Biotechnology, Healthcare and Hospitals, Health
2026-04-15 11:34 AM EDT | Scryb Inc.
Adia Nutrition, Inc. Announces Corporate Name Change to Adia Med, Inc. to Better Align with Its Regenerative Medicine and Biologics Business Model
Winter Park, Florida--(Newsfile Corp. - April 15, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a publicly traded company focused on regenerative medicine, stem cell therapies, and biologic products, today announced that it is in the process of changing its corporate name to Adia Med, Inc. The name change reflects the company's evolving business model, which has shifted significantly toward advanced medical treatments and biologics. Adia now operates through key divisions inclu
Healthcare and Hospitals, Health
2026-04-15 8:30 AM EDT | Adia Nutrition Inc.
FendX Engages Galenvs for Pilot Scale-Up Manufacturing of Its Liquid Surface Coating
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection solutions to reduce the spread of harmful pathogens, announces the signing of a statement of work ("SOW") dated April 14, 2026 with Galenvs Sciences Inc. ("Galenvs"), a Canadian contract manufacturing and service organization, to initiate pilot-scale manu
Technology, Healthcare and Hospitals, Health
2026-04-15 7:00 AM EDT | FendX Technologies Inc.
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
Ad hoc announcement pursuant to Art. 53 LR Long-term safety profile comparable to vehicle supports suitability for chronic use in a lifelong condition. Patients who remained on continuous Clascoterone treatment continued to gain hair through Month 12. In contrast, patients who switched to the placebo from Month 7 onwards experienced a reduction in treatment gains, demonstrating the importance of ongoing therapy. NDA a
Healthcare and Hospitals, Health
2026-04-15 1:07 AM EDT | Cosmo Pharmaceuticals N.V.
Jones Healthcare Group's Near-Term Emissions Reduction Targets Validated by the Science Based Targets Initiative
London, Ontario--(Newsfile Corp. - April 14, 2026) - Jones Healthcare Group's near-term greenhouse gas emissions reduction targets have been approved by the Science Based Targets initiative (SBTi), marking a significant step in the company's commitment to reducing emissions across its operations and broader value chain. As part of its validated targets, Jones commits to reduce absolute scope 1 and scope 2 greenhouse gas emissions 43.26% by 2030 from a 2023 base year. The company also c
Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-14 10:00 AM EDT | Jones Healthcare Group
Cheelcare to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
Markham, Ontario--(Newsfile Corp. - April 14, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, announced today that it will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference take place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. Cheelcare's CEO, Eugene Cherny and VP of Growth, Allan Boyd will present and participate in one-on-one meetings wit
Technology, Biotechnology, Investment Banking, Health
2026-04-14 7:30 AM EDT | Bloom Burton & Co. Inc.
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-04-14 7:27 AM EDT | Cardiol Therapeutics Inc.
Dr. Paula Muto, Founder of UberDoc, Appointed to U.S. Federal Health Advisory Committee
Boston, Massachusetts--(Newsfile Corp. - April 14, 2026) - UberDoc Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) ("UberDoc" or the "Company"), an innovative healthcare platform empowering patients to connect with top physicians directly at transparent, upfront prices, today announced that its Founder, Dr. Paula Muto, has been appointed to the National Committee on Vital and Health Statistics (NCVHS), a federal advisory body to U.S. Department of Health and Human Services (HHS) and Centers
2026-04-14 1:00 AM EDT | UberDoc
Rapid Dose Therapeutics (DOSE) (RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets
Burlington, Ontario--(Newsfile Corp. - April 13, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at its Burlington, Ontario manufacturing site, positioning the Company for pharmaceutical expansion, regulatory advancement, and global commercialization opportunities. The upgrade pro
2026-04-13 9:51 AM EDT | Rapid Dose Therapeutics Corp.
Fotonara and PhantomOmics Announce Revolutionary Partnership and "Good for All Humans" Initiative to Transform Affordable Housing into Sovereign Health Guardians
Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Fotonara Inc., a pioneer in advanced manufacturing and sovereign smart building infrastructure, and PhantomOmics Inc., a visionary in proactive health technology, today announced a landmark global commercialization partnership. Together, the two Calgary-based tech innovators are launching the "Good for All Humans" initiative—a sweeping joint mission to make high-fidelity, preventative health monitoring a standard, low-cost uti
Technology, Healthcare and Hospitals, Sensor, Health
2026-04-13 8:15 AM EDT | PhantomOmics Inc.
CURED Nutrition Joins One Hemp, Strengthening Industry Alignment Ahead of Key Federal Legislative Deadline
Washington, D.C.--(Newsfile Corp. - April 13, 2026) - CURED Nutrition, a Colorado-based wellness brand formulating non-intoxicating, full-spectrum cannabinoid supplements, today announced it has joined ONE HEMP, a national industry coalition advancing quality standards, transparency, and responsible federal regulation across the hemp CBD marketplace. The announcement comes as the industry approache
2026-04-13 7:55 AM EDT | OneHemp
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer, will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference. The conference is being held April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, O
Technology, Biotechnology, Investment Banking, Health
2026-04-13 7:30 AM EDT | Bloom Burton & Co. Inc.
WELL Health and WELLSTAR to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, and its majority-owned
Technology, Biotechnology, Investment Banking, Health
2026-04-13 7:30 AM EDT | Bloom Burton & Co. Inc.
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using it
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-04-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce that the Company will be participating as a presenting company at the 2026 Bloom Burton & Co. Healthcar
Technology, Biotechnology, Investment Banking, Health
2026-04-13 7:00 AM EDT | Bloom Burton & Co. Inc.
UberDoc Health Technologies Corp. Announces Upcoming Investor Webinar
Boston, Massachusetts--(Newsfile Corp. - April 13, 2026) - UberDoc Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) ("UberDoc" or the "Company") is pleased to announce that Sean Kearney, Chief Executive Officer, and Dr. Paula Muto, Founder and Chief Medical Advisor, will present an introduction to UberDoc in a live investor webinar taking place on Wednesday, April 15, 2026, at 11:00 AM PT / 2:00 PM ET.
2026-04-13 1:00 AM EDT | UberDoc
Voting Results of Cosmo's 2026 AGM
Dublin, Ireland--(Newsfile Corp. - April 10, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting (AGM). A total of 10,354,065 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 59.02% of the total outstanding ordinary shares in the share capital of Cosmo as of the record
Healthcare and Hospitals, Health
2026-04-10 9:16 AM EDT | Cosmo Pharmaceuticals N.V.